z-logo
open-access-imgOpen Access
Sulfonylurea Use During Entire Pregnancy in Diabetes Because of KCNJ11 Mutation: A Report of Two Cases
Author(s) -
Zsolt Gaál,
Tomasz Klupa,
Irene Kantor,
Wojciech Młynarski,
László Albert,
Justyna Tołłoczko,
István Balogh,
Krzysztof Czajkowski,
Maciej T. Małecki
Publication year - 2012
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc12-0163
Subject(s) - medicine , gliclazide , glibenclamide , diabetes mellitus , pregnancy , sulfonylurea , mutation , pediatrics , obstetrics , endocrinology , gene , genetics , biology
Mutations of the KCNJ11 gene are a common cause of permanent neonatal diabetes (PNDM) (1,2) and sometimes result in other diabetic phenotypes (2). Sulfonylureas (SUs) are effective and safe in most diabetic KCNJ11 mutation carriers (3). However, their application risk is sometimes uncertain. We have previously described glibenclamide use in a pregnant woman with KCNJ11 -related PNDM (4); for the first time, we report two cases treated with SU throughout the entire pregnancy.The first case was a Hungarian woman with the E229 K KCNJ11 mutation resulting in relapsing neonatal diabetes. The patient experienced remission between the ages of 3 and 10 years, at which point insulin was restarted. At the age of 13, after genetic testing, the patient was switched to gliclazide 60 mg/day. The woman became pregnant at the age of 16 years. When she was referred …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom